Development and evaluation of a first-in-class CAR-T therapy against calreticulin-mutant neoplasms
Alex Rampotas, MBBS, MRCP, University College London, London, UK, and Zoë Wong, BSc, University of Oxford, Oxford, UK, discuss the development and evaluation of a novel CAR T-cell therapy targeting mutated calreticulin in myelofibrosis (MF), a disease in which novel targeted treatment options are needed. The therapy was initially tested in vitro in cell lines and in vivo in a murine model before being evaluated in a human bone marrow organoid model. Testing the CAR-T in this organoid model, which utilizes primary patient cells, allows its efficacy to be assessed in a relevant human tissue microenvironment. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
